Topic Hub
7 clinically reviewed articles, written and peer-reviewed by the HealthRX.com Medical Team.
Explore
Showing 7 of 7 clinical reviews.
A detailed look at the legal status of compounding lisdexamfetamine (Vyvanse), including FDA regulations under 503A/503B, DEA Schedule II restrictions, and state-level rules.
Read clinical reviewA detailed comparison of how the FDA and EMA evaluated, labeled, and monitor lisdexamfetamine (Vyvanse), including approval dates, label differences, post-market surveillance programs, and what each means for prescribers and patients.
Read clinical reviewA clinical deep-dive into Vyvanse (lisdexamfetamine) FAERS adverse event reports, FDA label warnings, and post-market surveillance data, reviewed by the HealthRX medical team.
Read clinical reviewA complete timeline of Vyvanse (lisdexamfetamine) FDA approvals, label expansions, safety updates, and generic entry, with primary-source citations from Drugs@FDA and PubMed.
Read clinical reviewA comprehensive review of lisdexamfetamine (Vyvanse) regulatory status worldwide, including FDA approval history, EMA authorization, scheduling classifications, label updates, and ongoing safety monitoring.
Read clinical reviewA detailed review of Vyvanse (lisdexamfetamine) patent litigation, Hatch-Waxman challenges, FDA approval timeline, and the path to generic availability.
Read clinical reviewA comprehensive look at lisdexamfetamine (Vyvanse) regulatory history, current FDA label, post-market safety data, and what the pipeline holds for next-generation ADHD and BED pharmacotherapy.
Read clinical review